Zobrazeno 1 - 7
of 7
pro vyhledávání: '"DNA damage response inhibitor"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiang-Zhong Liu, Mi Zhou, Chun-Chun Du, Hong-Hong Zhu, Xi Lu, Shou-Lun He, Guang-Hui Wang, Ting Lin, Wen-Jing Tian, Hai-Feng Chen
Publikováno v:
Biomedicines, Vol 9, Iss 10, p 1473 (2021)
(±)-Hypersines A–C (1–3), the three pairs of enantiomerically pure monoterpenoid polyprenylated acylphloroglucinols with an unprecedented 6/6/5/4 fused ring system, were isolated from Hypericum elodeoides. Their structures, including absolute co
Externí odkaz:
https://doaj.org/article/1ce9ed445995477387859556503cd17c
Publikováno v:
Cells, Vol 9, Iss 9, p 2012 (2020)
DNA damage response inhibitors (DDRi) may selectively enhance the inactivation of tumor cells in combination with ionizing radiation (IR). The induction of senescence may be the key mechanism of tumor cell inactivation in this combinatorial treatment
Externí odkaz:
https://doaj.org/article/89778952c7f142d7b3ee5fc482d6e5e7
Autor:
Tom Haswell, Matthew G Krebs, Chris J. Twelves, Katrina Walker, Corinne Faivre-Finn, David Sebag-Montefoire, Paul Shaw, Ahmed Salem, Nicola L. Hannaway, Anthony J. Chalmers, Alexandra Gilbert, R. Young, Geraldine Murden, Crispin T. Hiley, Sarah Brown, Jamie B. Oughton, Gerard G Hanna, Anderson J. Ryan, Rachel Phillip, Alastair Greystoke, Fiona Collinson, Kevin Franks, Martin Forster, Gerard Walls, Stephen Harrow, Samantha Hinsley
Publikováno v:
Walls, G M, Oughton, J B, Chalmers, A J, Brown, S, Collinson, F, Forster, M D, Franks, K N, Gilbert, A, Hanna, G G, Hannaway, N, Harrow, S, Haswell, T, Hiley, C T, Hinsley, S, Krebs, M, Murden, G, Phillip, R, Ryan, A J, Salem, A, Sebag-Montefoire, D, Shaw, P, Twelves, C J, Walker, K, Young, R J, Faivre-Finn, C & Greystoke, A 2020, ' CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer ', Clinical and translational radiation oncology, vol. 25, pp. 61-66 . https://doi.org/10.1016/j.ctro.2020.09.006
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 25, Iss, Pp 61-66 (2020)
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 25, Iss, Pp 61-66 (2020)
Highlights • Lung cancer is the leading cause of cancer mortality worldwide. • Gold standard chemoradiotherapy is not deliverable for the majority of patients. • Radiation-induced DNA damage repair is an actionable mechanism of radioresistance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab793db3c955a860dc79fcb06479e299
https://pure.qub.ac.uk/en/publications/concorde-a-phase-i-platform-study-of-novel-agents-in-combination-with-conventional-radiotherapy-in-nonsmallcell-lung-cancer(7a8b2ae9-083a-4970-a3aa-cc71031461f1).html
https://pure.qub.ac.uk/en/publications/concorde-a-phase-i-platform-study-of-novel-agents-in-combination-with-conventional-radiotherapy-in-nonsmallcell-lung-cancer(7a8b2ae9-083a-4970-a3aa-cc71031461f1).html
Publikováno v:
Cells
Cells, Vol 9, Iss 2012, p 2012 (2020)
Volume 9
Issue 9
Cells, Vol 9, Iss 2012, p 2012 (2020)
Volume 9
Issue 9
DNA damage response inhibitors (DDRi) may selectively enhance the inactivation of tumor cells in combination with ionizing radiation (IR). The induction of senescence may be the key mechanism of tumor cell inactivation in this combinatorial treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e77fb7fa58feb20ee5c55641f1898695
https://pubmed.ncbi.nlm.nih.gov/32883016
https://pubmed.ncbi.nlm.nih.gov/32883016
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Walls GM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK., Oughton JB; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Chalmers AJ; Institute of Cancer Sciences, University of Glasgow, Scotland, UK., Brown S; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Collinson F; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Forster MD; Department of Oncology, UCL Cancer Institute, England, UK., Franks KN; St James' Institute of Oncology, University of Leeds, England, UK., Gilbert A; St James' Institute of Oncology, University of Leeds, England, UK., Hanna GG; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia., Hannaway N; Newcastle University, Newcastle upon Tyne, England, UK., Harrow S; The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK., Haswell T; Patient and Public Involvement Advocacy, UK., Hiley CT; Department of Oncology, UCL Cancer Institute, England, UK., Hinsley S; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Institute of Cancer Sciences, University of Glasgow, Scotland, UK., Krebs M; Faculty of Biology, Medicine and Health, University of Manchester, England, UK., Murden G; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Phillip R; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Ryan AJ; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK., Salem A; The Christie NHS Foundation Trust/University of Manchester, Manchester, England, UK., Sebag-Montefoire D; St James' Institute of Oncology, University of Leeds, England, UK., Shaw P; Velindre University NHS Trust, Cardiff, Wales, UK., Twelves CJ; St James' Institute of Oncology, University of Leeds, England, UK., Walker K; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK., Young RJ; Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, England, UK., Faivre-Finn C; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK., Greystoke A; Newcastle University, Newcastle upon Tyne, England, UK.
Publikováno v:
Clinical and translational radiation oncology [Clin Transl Radiat Oncol] 2020 Sep 22; Vol. 25, pp. 61-66. Date of Electronic Publication: 2020 Sep 22 (Print Publication: 2020).